Author

M. Petrucci

Observed names: M Petrucci, MT Petrucci, MT. Petrucci, Maria T. Petrucci, Petrucci, Maria

Institution: Policlinico Umberto I

Observed institutions: Policlinico Umberto I, Sapienza University of Rome

OpenAlex ID: A5111867970

Beyond Single Pathway Inhibition: MEK Inhibitors as a Platform for the Development of Pharmacological Combinations with Synergistic Anti-Leukemic Effects

2005 · M. Milella, C. Precupanu, et al. · Current Pharmaceutical Design · 56

First-line therapy with daratumumab, lenalidomide and dexamethasone for patient with POEMS syndrome: A case report

2024 · E. Amabile, F. Fazio, et al. · Leukemia Research Reports · 4

A246 VMP Results in Fewer Bone Events and Greater ALP Increases Versus MP in the VISTA Study in Front-Line MM

2009 · M Delforge, M Kropff, et al. · Clinical Lymphoma & Myeloma · 3

Addressing unmet needs in relapsed/refractory multiple myeloma: an Italian Delphi consensus on current challenges and emerging therapies

2026 · Michele Cavo, Sara Bringhen, et al. · Frontiers in Oncology · 1

B267 MEK/ERK and Mevalonate Pathways Inhibition in Multiple Myeloma

2009 · MR Ricciardi, M Milella, et al. · Clinical Lymphoma & Myeloma

GM-CSF/IL3 fusion protein (pixy 321) and other growth factors in acute myeloid leukemia blasts

1995 · A. Tafuri, T. Valentini, et al. · European Journal of Cancer

Works count: 7

Citation count: 64

H-index: 3

I10-index: 1